However, it is worth noting that most preclinical studies do not incorporate a dose titration phase, a gradual increase to the therapeutic maintenance dose, which is standard in clinical settings
If a patient depends only on appetite suppression, maintenance may become difficult when appetite changes or medication access changes
Patients should only use GLP-1 medications prescribed by licensed healthcare providers and obtained through legitimate pharmacies, ensuring product authenticity and appropriate medical supervision
A phase 2 trial assessing different doses of bimagrumab (up to 30 mg/kg) in combination with semaglutide as obesity treatment is ongoing (NCT05616013)
Possible side effects include nausea, bloating, lightheadedness, and dehydration, especially early in treatment
10.34172/apb.43672 94 ZhengZ.ZongY.MaY.TianY.PangY.ZhangC.et al (2024)